Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
Apnimed announced five abstracts accepted for presentation at CHEST 2026, including two late-breakers featuring Phase 3 data on AD109 in obstructive sleep apnea. CHEST will also host a panel on the Phase 3 SynAIRgy and LunAIRo trial results, and Apnimed will sponsor a learning theater on the investigational oral tablet.
Key figures
- Drug Name
- AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg)
- Phase Of Trial
- Phase 3
- Pdufa date
- February 28, 2027
- Abstracts accepted
- 5
- Late breaking abstracts
- 2
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.